Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Update

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 139,100 shares, a decline of 6.0% from the January 15th total of 148,000 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 13,200 shares, the days-to-cover ratio is currently 10.5 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC bought a new position in Eupraxia Pharmaceuticals during the fourth quarter valued at approximately $31,000. Raymond James Financial Inc. bought a new position in Eupraxia Pharmaceuticals during the fourth quarter valued at approximately $37,000. Finally, Bank of Montreal Can boosted its stake in shares of Eupraxia Pharmaceuticals by 15.2% during the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock valued at $178,000 after purchasing an additional 7,500 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Rodman & Renshaw assumed coverage on Eupraxia Pharmaceuticals in a research report on Thursday, November 14th. They set a "buy" rating and a $9.00 price target for the company. Craig Hallum assumed coverage on shares of Eupraxia Pharmaceuticals in a research report on Friday. They issued a "buy" rating and a $12.00 price objective on the stock. Finally, RODMAN&RENSHAW upgraded shares of Eupraxia Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, November 14th.

Eupraxia Pharmaceuticals Price Performance

NASDAQ EPRX traded up $0.10 on Friday, reaching $3.65. 56,882 shares of the company's stock traded hands, compared to its average volume of 12,149. Eupraxia Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $5.15. The stock has a 50-day simple moving average of $3.13 and a 200 day simple moving average of $2.90. The stock has a market cap of $130.12 million and a PE ratio of -5.07.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.